Zuberitamab
- Generic Name
- Zuberitamab
- Indication
用于CD20阳性弥漫大B细胞淋巴瘤，非特指性（DLBCL，NOS）成人患者，应与标准CHOP化疗（环磷酰胺、阿霉素、长春新碱、泼尼松）联合治疗。
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT06757894
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Phase 2
Not yet recruiting
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06642909
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath